Don Berry
#46,443
Most Influential Person Now
American statistician
Don Berry 's AcademicInfluence.com Rankings
Don Berry mathematics Degrees
Mathematics
#2610
World Rank
#3999
Historical Rank
#1020
USA Rank
Statistics
#223
World Rank
#278
Historical Rank
#90
USA Rank
Download Badge
Mathematics
Don Berry 's Degrees
- PhD Statistics University of California, Berkeley
- Masters Statistics University of California, Berkeley
- Bachelors Mathematics University of California, Berkeley
Similar Degrees You Can Earn
Why Is Don Berry Influential?
(Suggest an Edit or Addition)According to Wikipedia, Donald Arthur Berry is an American statistician and a practitioner and proponent of Bayesian statistics in medical science. He was the chairman of the Department of Biostatistics and Applied Mathematics at the University of Texas M. D. Anderson Cancer Center from 1999-2010, where he played a role in the use of Bayesian methods to develop innovative, adaptive clinical trials. He is best known for the development of statistical theory relating to the design of clinical trials. He is a fellow of the American Statistical Association and the Institute of Mathematical Sciences. He founded Berry Consultants, a statistical consulting group, with Scott Berry in 2000.
Don Berry 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
- Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. (2003) (1462)
- Effect of screening and adjuvant therapy on mortality from breast cancer (2005) (1380)
- Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. (2003) (1284)
- Effect of screening and adjuvant therapy on mortality from breast cancer. (2006) (1204)
- Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. (2015) (1151)
- Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. (2005) (1123)
- Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. (2010) (1087)
- Benefits and harms of CT screening for lung cancer: a systematic review. (2012) (1076)
- c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. (1994) (979)
- Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. (2004) (958)
- The decrease in breast-cancer incidence in 2003 in the United States. (2007) (949)
- Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. (2013) (900)
- Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. (1998) (745)
- Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). (2015) (726)
- erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. (1998) (625)
- Bayesian clinical trials (2006) (602)
- Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. (2009) (600)
- Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. (2008) (571)
- Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. (1998) (566)
- Endoscopic release of the carpal tunnel: a randomized prospective multicenter study. (1992) (536)
- BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. (2002) (488)
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative (2012) (474)
- Bandit Problems: Sequential Allocation of Experiments. (1986) (439)
- HER2 and response to paclitaxel in node-positive breast cancer. (2007) (433)
- Detecting an overall survival benefit that is derived from progression-free survival. (2009) (429)
- High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. (2009) (426)
- Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. (2016) (422)
- Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. (2006) (418)
- Addressing overdiagnosis and overtreatment in cancer: a prescription for change. (2014) (414)
- Statistical Analysis and the Illusion of Objectivity (1988) (401)
- Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. (2005) (386)
- Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. (1997) (380)
- Statistics: Theory and Methods (1990) (367)
- Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer (2006) (361)
- DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. (2010) (333)
- Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis (2017) (322)
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. (2020) (319)
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) (2011) (318)
- Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. (2012) (317)
- Characterization of BRCA1 and BRCA2 mutations in a large United States sample. (2006) (316)
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. (2016) (301)
- Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. (2014) (270)
- Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. (2005) (253)
- Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. (2011) (235)
- Statistics: A Bayesian Perspective (1995) (233)
- Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. (2004) (229)
- Adjuvant chemotherapy in older women with early-stage breast cancer. (2009) (220)
- Adaptive clinical trials in oncology (2012) (220)
- Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. (2016) (219)
- Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. (2007) (215)
- Statistical Methodology in the Pharmaceutical Sciences (1989) (203)
- MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation (2006) (201)
- Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies (2016) (201)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. (2017) (197)
- Statistical models in epidemiology, the environment, and clinical trials (2000) (192)
- Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. (1995) (191)
- Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. (2005) (191)
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody (2020) (190)
- Logarithmic transformations in ANOVA. (1987) (186)
- Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012 (2018) (185)
- HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. (2000) (182)
- A case for Bayesianism in clinical trials. (1993) (175)
- Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. (2002) (175)
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses (2014) (173)
- Bayesian Statistics and the Efficiency and Ethics of Clinical Trials (2004) (167)
- Meta-Analysis in Medicine and Health Policy (2000) (159)
- Adaptive clinical trials: the promise and the caution. (2011) (158)
- Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. (2000) (156)
- Bandit problems with infinitely many arms (1997) (153)
- Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 (2006) (152)
- Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. (1999) (148)
- The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee (2010) (145)
- Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). (2015) (140)
- Accounting for Multiplicities in Assessing Drug Safety: A Three‐Level Hierarchical Mixture Model (2004) (140)
- Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study (2020) (139)
- NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. (2009) (139)
- Adaptive Bayesian Designs for Dose-Ranging Drug Trials (2002) (137)
- Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials (2013) (135)
- Bayesian perspectives on multiple comparisons (1999) (133)
- Adaptive platform trials: definition, design, conduct and reporting considerations (2019) (132)
- Seamlessly Expanding a Randomized Phase II Trial to Phase III (2002) (131)
- Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. (1998) (127)
- Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. (2014) (123)
- Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. (2020) (122)
- Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. (2014) (117)
- A Parallel Phase I/II Clinical Trial Design for Combination Therapies (2007) (116)
- Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. (2005) (114)
- Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. (2010) (112)
- Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. (2001) (111)
- Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. (2001) (109)
- Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE (2017) (109)
- Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer (2018) (109)
- Interim analyses in clinical trials: classical vs. Bayesian approaches. (1985) (109)
- Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. (2006) (106)
- A Bernoulli Two-armed Bandit (1972) (106)
- Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. (2003) (104)
- Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center (2009) (100)
- Bayesian multiple comparisons using dirichlet process priors (1998) (99)
- Benefits and risks of screening mammography for women in their forties: a statistical appraisal. (1998) (99)
- High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. (2011) (99)
- Interim analysis in clinical trials; the role of the likelihood principle (1987) (98)
- One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. (1988) (97)
- Group sequential clinical trials: a classical evaluation of Bayesian decision-theoretic designs (1994) (94)
- Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer (2012) (90)
- Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis (2005) (90)
- Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development (2009) (89)
- PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer (2013) (88)
- Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. (2003) (87)
- Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance) (2016) (86)
- Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. (2020) (85)
- Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. (2008) (84)
- Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules: Model estimates of potential benefits and harms (Annals of Internal Medicine (2009) 151, (738-747)) (2010) (83)
- Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer (2010) (83)
- Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. (2012) (83)
- Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality (2009) (83)
- The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer (2015) (82)
- Statistical Decision Theory, Foundations, Concepts, and Methods (1982) (81)
- Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. (2013) (79)
- Association of angiogenesis in lymph node metastases with outcome of breast cancer. (2000) (79)
- Statistical Inference in Crime Investigations Using Deoxyribonucleic Acid Profiling (1992) (79)
- Empirical Bayes Estimation of a Binomial Parameter Via Mixtures of Dirichlet Processes (1979) (78)
- Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL (2013) (78)
- Simulation-based sequential Bayesian design (2007) (78)
- Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). (2014) (76)
- Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. (2003) (75)
- High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. (2002) (75)
- The Relevance of Stopping Rules in Statistical Inference (1988) (73)
- Adaptive clinical trials: a partial remedy for the therapeutic misconception? (2012) (72)
- The science of doping (2008) (72)
- Teaching Elementary Bayesian Statistics with Real Applications in Science (1997) (72)
- Pre-counseling education materials for BRCA testing: does tailoring make a difference? (2002) (71)
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. (2021) (71)
- High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. (2011) (70)
- Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer (1998) (68)
- Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. (1997) (67)
- Research issues affecting preoperative systemic therapy for operable breast cancer. (2008) (66)
- Monitoring accumulating data in a clinical trial. (1989) (66)
- Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. (1999) (65)
- em Bayesian analysis in statistics and econometrics (1997) (63)
- Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis (2007) (63)
- Validity of Models for Predicting BRCA1 and BRCA2 Mutations (2007) (63)
- Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) (2013) (63)
- Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. (1998) (62)
- Bayesian analysis in statistics and econometrics : essays in honor of Arnold Zellner (1996) (61)
- DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial (2017) (61)
- Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer (2006) (60)
- Inferences Using DNA Profiling in Forensic Identification and Paternity Cases (1991) (60)
- Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) (2016) (59)
- Choosing sample size for a clinical trial using decision analysis (2003) (58)
- Symmetrized Percent Change for Treatment Comparisons (2006) (55)
- Relationship Between Bayesian and Frequentist Sample Size Determination (2005) (54)
- Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease (2016) (53)
- Optimal adaptive randomized designs for clinical trials (2007) (53)
- Modified Two-Armed Bandit Strategies for Certain Clinical Trials (1978) (52)
- Using short‐term response information to facilitate adaptive randomization for survival clinical trials (2009) (52)
- Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes (1998) (52)
- MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. (2019) (50)
- Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). (2015) (50)
- Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. (1999) (49)
- Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. (2020) (48)
- Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer (2018) (48)
- Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. (2002) (47)
- Introduction to Probability and Statistics (4th ed.). (1980) (47)
- Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. (2009) (47)
- The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. (1997) (45)
- Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. (1999) (45)
- Monitoring a clinical trial conducted under the Food and Drug Administration regulations allowing a waiver of prospective informed consent: the diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial. (2001) (44)
- Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval. (2015) (44)
- Optimal designs for clinical trials with dichotomous responses. (1985) (43)
- From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. (2015) (43)
- Building a roadmap for developing combination therapies for Alzheimer’s disease (2015) (43)
- Statistical Innovations in Cancer Research (2003) (43)
- Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. (2019) (42)
- A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarizations: a meta-analysis. (1990) (42)
- A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug (2010) (41)
- Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials (2012) (41)
- Bernoulli One-Armed Bandits--Arbitrary Discount Sequences (1979) (41)
- Recommended changes to oncology clinical trial design: revolution or evolution? (2008) (40)
- Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation (2007) (39)
- Multiplicities in cancer research: ubiquitous and necessary evils. (2012) (39)
- CNS Anticancer Drug Discovery and Development Conference White Paper. (2015) (39)
- An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. (2012) (39)
- Bayesian Survival Analysis With Nonproportional Hazards (2004) (38)
- A Bayesian Decision-Theoretic Dose-Finding Trial (2006) (38)
- Cancer genomics: promises and complexities. (2001) (35)
- Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. (1994) (35)
- Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. (2012) (35)
- Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. (1999) (35)
- Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach (2017) (34)
- CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). (2019) (34)
- Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. (2013) (34)
- Decision making during a phase III randomized controlled trial. (1994) (34)
- Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes (2010) (33)
- Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium. (2009) (32)
- Flawed inferences about screening mammography's benefit based on observational data. (2009) (32)
- Charting a path toward combination therapy for Alzheimer’s disease (2015) (32)
- Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. (2004) (32)
- p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905) (2011) (32)
- Breast cancer screening: controversy of impact. (2013) (31)
- The past is the future: innovative designs in acute stroke therapy trials. (2005) (31)
- Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer (2018) (31)
- From drug discovery to biomarker-driven clinical trials in lymphoma (2012) (31)
- Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. (2015) (31)
- Comment: Ethics and ECMO (1989) (31)
- Signature program: a platform of basket trials (2018) (31)
- A Bayesian group sequential design for a multiple arm randomized clinical trial. (1995) (30)
- Elacytarabine has single‐agent activity in patients with advanced acute myeloid leukaemia (2012) (30)
- Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis (2015) (30)
- Prognostic Role of Detection Method and Its Relationship with Tumor Biomarkers in Breast Cancer: The University of Texas M. D. Anderson Cancer Center Experience (2008) (30)
- Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. (2011) (29)
- Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. (2008) (29)
- Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial) (2012) (29)
- Assessing probability of ancestry using simple sequence repeat profiles: applications to maize hybrids and inbreds. (2002) (29)
- Decision analysis and Bayesian methods in clinical trials. (1995) (28)
- Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL (2014) (28)
- Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). (2014) (28)
- Overestimation of hereditary breast cancer risk. (1998) (28)
- Advancing Clinical Trials to Streamline Drug Development (2015) (28)
- The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context (2013) (27)
- Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. (2015) (27)
- A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies (1996) (27)
- Genetic Susceptibility and Survival: Application to Breast Cancer (2000) (26)
- Relation of glutathione S-transferase α and μ isoforms to response to therapy in human breast cancer (1997) (26)
- Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. (2020) (26)
- Experimental design for drug development: a Bayesian approach. (1991) (26)
- Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. (2002) (26)
- Assessing differential drug effect. (1984) (26)
- Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. (2011) (25)
- Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869. (1995) (25)
- Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806 (2006) (25)
- Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. (2021) (24)
- Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL. (2018) (24)
- Modeling the impact of population screening on breast cancer mortality in the United States. (2011) (24)
- Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. (2003) (23)
- Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease (2015) (23)
- Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models (2018) (23)
- Breast cancer trends: a marriage between clinical trial evidence and epidemiology. (2007) (23)
- Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. (2015) (22)
- Bayesian approaches for comparative effectiveness research (2012) (22)
- Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials (2013) (22)
- Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009 (2012) (22)
- Assessing probability of ancestry using simple sequence repeat profiles: applications to maize inbred lines and soybean varieties. (2003) (21)
- Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc (2015) (21)
- Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project (2016) (21)
- Addressing the Incremental Benefit of Histamine Dihydrochloride When Added to Interleukin-2 in Treating Acute Myeloid Leukemia: A Bayesian Meta-Analysis (2011) (21)
- Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial (2021) (21)
- Failure of researchers, reviewers, editors, and the media to understand flaws in cancer screening studies: Application to an article in Cancer (2014) (20)
- Bayesian Meta-Analyses for Comparative Effectiveness and Informing Coverage Decisions (2010) (20)
- Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes (2018) (20)
- Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL (2020) (20)
- Primary Hyperparathyroidism and Osteosarcoma: Examination of a Large Cohort Identifies Three Cases of Fibroblastic Osteosarcoma (2005) (19)
- A p-Value to Die For (2017) (19)
- Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009 (2012) (18)
- Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. (2003) (18)
- Commentary on Hey and Kimmelman (2015) (18)
- Adaptive Trials and Bayesian Statistics in Drug Development (2002) (17)
- Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL (2016) (17)
- Adaptive trial design. (2007) (17)
- Clinical trials: is the Bayesian approach ready for prime time? Yes! (2005) (17)
- The screening mammography paradox: better when found, perhaps better not to find (2008) (17)
- Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer (2020) (17)
- Dual inhibition of IGFR and mTOR pathways. (2010) (17)
- Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL (2020) (16)
- Modeling Risk of Breast Cancer and Decisions about Genetic Testing (1999) (16)
- Optimal Sampling Schemes for Estimating System Reliability by Testing Components—I: Fixed Sample Sizes (1974) (16)
- Bias and trials stopped early for benefit. (2010) (16)
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. (2008) (16)
- Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma, (2011) (16)
- NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. (2014) (16)
- Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. (2012) (15)
- Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944) (2009) (15)
- Discrete Search with Directional Information (1986) (15)
- An Improved Procedure for Selecting the Better of Two Bernoulli Populations (1973) (15)
- Evaluation of cell-free DNA approaches for multi-cancer early detection. (2022) (15)
- Applications of Lindley Information Measure to the Design of Clinical Experiments (1994) (15)
- Bayesian nonparametric bandits (1985) (15)
- Validating Bayesian Prediction Models: a Case Study in Genetic Susceptibility to Breast Cancer (1999) (15)
- CYP2D6 Genotype and Adjuvant Tamoxifen (2014) (14)
- Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer (2018) (14)
- A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality (2017) (14)
- Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process—Findings from a qualitative study (2015) (14)
- The hazards of endpoints. (2010) (14)
- Bayesian Methods in Phase III Trials (1991) (13)
- CYP2D6 genotyping and the use of tamoxifen in breast cancer. (2013) (13)
- Statistical Inference, Designing Clinical Trials, and Pharmaceutical Company Decisions (1987) (13)
- Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511) (2016) (13)
- Creating a synthetic control arm from previous clinical trials: Application to establishing early end points as indicators of overall survival in acute myeloid leukemia (AML). (2017) (13)
- Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial (2020) (13)
- Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG (2005) (13)
- Bayesian Continual Reassessment Method for Dose-Finding Trials Infusing T Cells with Limited Sample Size (2012) (13)
- CpG Island Methylation Is a Poor Prognostic Factors in Myelodysplastic Syndrome Patients and Is Reversed by Decitabine Therapy-Results of a Phase III Randomized Study. (2005) (12)
- Breast Cancer Research and Treatment 2001 Reviewers (2004) (12)
- A Cost/Benefit Analysis of Clinical Trial Designs for COVID-19 Vaccine Candidates (2020) (12)
- Bayesian predictions of final outcomes: regulatory approval of a spinal implant (2005) (12)
- The Probability of a Field Goal: Rating Kickers (1985) (12)
- Immunologic Aspects of Chronic Obstructive Pulmonary Disease (2009) (12)
- Bayesian Methods in Health-Related Research (2018) (11)
- Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance). (2015) (11)
- Interim analyses in clinical research. (1987) (11)
- Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041) (2004) (11)
- Meta-analysis: Past and Present Challenges (2000) (11)
- Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL (2016) (10)
- Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer (2015) (10)
- Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL (2021) (10)
- Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. (1997) (10)
- Predicting clinical trial results based on announcements of interim analyses (2014) (10)
- Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. (2008) (10)
- When is a confirmatory randomized clinical trial needed? (1996) (10)
- A Bayesian Approach to Multicenter Trials and Metaanalysis. (1989) (10)
- Commentary: screening mammography: a decision analysis. (2004) (10)
- Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). (2017) (9)
- 532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial (2014) (9)
- Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab (2018) (9)
- The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines (2010) (9)
- Subgroup analyses. (1990) (9)
- A nonparametric Bayesian basket trial design (2016) (8)
- Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial (2017) (8)
- Computer-assisted detection and screening mammography: where's the beef? (2011) (8)
- Application of second-order polynomial equations to the study of pharmacodynamic interactions: the effect of flecainide acetate and propranolol on cardiac output and vascular resistance. (1984) (8)
- GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. (2020) (8)
- Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3,490 patients included in two randomized trials (2007) (8)
- Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial. (2021) (8)
- Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma (2010) (7)
- Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer (2021) (7)
- Bernoulli two-armed bandits with geometric termination (1981) (7)
- Worth of perfect information in bernoulli bandits (1991) (7)
- Neoadjuvant as Future for Drug Development in Breast Cancer—Response (2016) (7)
- Regression analysis applied to PVC histories: a statistical procedure for evaluating antiarrhythmic drug efficacy. (2007) (7)
- Power of chronobiologic pilots: a statistician's opinion. (1993) (7)
- The Bayesian principle: can we adapt? (2005) (7)
- Validated biomarker signatures that predict pathologic response to preoperative chemoradiation therapy (CTRT) with high specificity and desirable sensitivity levels in patients with esophageal cancer (EC). (2011) (7)
- Genetic diversity among U.S. sunflower inbreds and hybrids: assessing probability of ancestry and potential for use in plant variety protection. (2009) (7)
- Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148). (2009) (7)
- Impact of screening mammography on breast cancer mortality (2016) (7)
- Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma (2021) (7)
- Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. (2021) (7)
- Statistical inference and the design of clinical trials. (1980) (7)
- DNA, Statistics, and the Simpson Case (1994) (7)
- Variability of different methods for measurement of ECG intervals and ECG interval temporal variation. (1989) (6)
- Biomarker studies and other difficult inferential problems: statistical caveats. (2007) (6)
- Inferences about Testosterone Abuse among Athletes (2004) (6)
- Assessing the benefits of testing for breast cancer susceptibility genes: a decision analysis. (1998) (6)
- A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network (2017) (6)
- Red-and-Black with Unknown Win Probability (1974) (6)
- Two-armed bandits with a goal, II. Dependent arms (1980) (6)
- Screening mammography for women in their forties. (1998) (6)
- High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: A phase II trial of the Cancer and Leukemia Group B (CALGB) (2004) (5)
- Using Historical Controls in Clinical Trials: Application to ECMO (1994) (5)
- DNA Fingerprinting: What Does it Prove? (1990) (5)
- Two-armed bandits with a goal, I. One arm known (1980) (5)
- Determining joint carrier probabilities of cancer‐causing genes using Markov chain Monte Carlo methods (2005) (5)
- Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial. (2019) (5)
- Building and validating a prognostic index for biomarker studies. (2006) (5)
- Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL (2020) (5)
- Breast cancer heterogeneity may explain peaks in recurrence. (2005) (5)
- Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop (2020) (5)
- Role of population-based studies in assessing genetic cancer risk. (2001) (5)
- Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis (2022) (4)
- A new Bayesian approach incorporating covariate information for heterogeneity and its comparison with HLOD (2005) (4)
- Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration In Follicular Lymphoma Patients (2010) (4)
- Inferential Aspects of Adaptive Allocation Rules. (1990) (4)
- Optimality of myopic stopping times for geometric discounting (1988) (4)
- Bayesian Multiple Comparisons Using Dirichlet Process (1996) (4)
- Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial (2017) (4)
- A Note on Inverse Sampling Procedures for Selecting the Best Binomial Population (1977) (4)
- Bias and Trials Stopped Early for Benefit. Authors' reply (2010) (4)
- Bounded limits and statistical inference in chronobiometry. (1990) (4)
- The role of HER-2 + Topo IIα amplification in predicting benefit from CAF dose escalation-CALGB 8541. (2004) (4)
- FDA recalls not as alarming as they seem. (2011) (4)
- A response-adaptive design of initial therapy for emergency department patients with heart failure. (2017) (4)
- Bandit Problems with Random Discounting (1983) (4)
- [DNA Fingerprinting: A Review of the Controversy]: Comment (1994) (4)
- Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19 (2021) (4)
- General keynote: clinical trial design. (2003) (4)
- PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First‐Line ± Standard‐of‐Care Therapies in Advanced NSCLC: Topic: Medical Oncology (2016) (4)
- Statisticians Introduce Science to International Doping Agency: The Andrus Veerpalu Case (2014) (4)
- Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer (2015) (4)
- Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study (2021) (4)
- The authors reply [13] (2008) (4)
- The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat, (2011) (4)
- Limited family structure and breast cancer risk. (2007) (3)
- Abstract P3-06-05: Evaluation of anin vitroderived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL: (2015) (3)
- Using biomarkers prospectively in adaptive clinical trials (2011) (3)
- Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance). (2013) (3)
- Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S. women, 2000-2017. (2022) (3)
- Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907. (2015) (3)
- Stereotactic ablative radiotherapy in operable stage I NSCLC patients: Long-term results of the expanded STARS clinical trial. (2021) (3)
- The signature program, a series of tissue-agnostic, mutation-specific signal finding trials. (2014) (3)
- Maximizing the length of a success run for many-armed bandits (1983) (3)
- 247: High-Dose Chemotherapy with Autologous Stem-Cell Support Versus Standard-Dose Chemotherapy for High-Risk Breast Cancer: Meta-Analysis of Individual Patient Data from 15 Randomized Adjuvant Trials (2008) (3)
- P53 Is axillary lymph node dissection indicated for early stage breast cancer? A decision analysis (1998) (3)
- Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question-Reply. (2017) (3)
- Author Correction: Adaptive platform trials: definition, design, conduct and reporting considerations (2019) (3)
- Floor discussion (2005) (3)
- Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma. (2016) (3)
- Transforming the clinical trial process: The I-SPY 2 trial as a model for improving the efficiency of clinical trials and accelerating the drug-screening process. (2014) (3)
- Statistics : a Bayesian perspective : student solutions manual (1996) (3)
- Abstract 859: Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer (2016) (3)
- HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL. (2019) (3)
- PANEL 2 Improved Insights into Effects of Cancer Therapies (2008) (2)
- COMMENT ON: DOSE AND DOSE INTENSITY AS DETERMINANTS OF OUTCOME IN THE ADJUVANT TREATMENT OF BREAST CANCER. AUTHOR'S REPLY (1999) (2)
- Simulation-Based Sequential Bayesian Design 1 (2006) (2)
- Discussion: Current Issues in the Design of Ovarian Cancer Treatment Trials (2003) (2)
- Optimal designs for clinical trials in stages (1995) (2)
- Bayesian Approaches to Randomized Trails - Discusion (1994) (2)
- The pharmacodynamic and pharmacokinetic interaction of flecainide acetate with propranolol: Effects on cardiac function and drug clearance (2004) (2)
- Abstract P2-11-02: A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL (2017) (2)
- Abstract 3594: Adaptively randomized seamless-phase multiarm platform trial: Glioblastoma Multiforme Adaptive Global Innovative Learning Environment (GBM AGILE) (2017) (2)
- Phosphorylation of AKT kinase substrates to predict response to the AKT inhibitor MK2206 in the I-SPY 2 trial in both HER2- and HER2+ patients. (2018) (2)
- Poly-ligand profiling (PLP) to differentiate pancreatic cancer patients who benefit from gemcitabine+evofosfamide versus gemcitabine+placebo treatment. (2018) (2)
- 413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy–Results From CALGB/Intergroup 9741 (2012) (2)
- Precision medicine: Preliminary results from the initiative for molecular profiling and advanced cancer therapy 2 (IMPACT 2) study (2019) (2)
- Sequential Statistical Methods (2015) (2)
- Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology (2022) (2)
- Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC). (2022) (2)
- Abstract P4-05-03: Mutational analysis of triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) (2020) (2)
- Biostatistics and Bioinformatics in Clinical Trials (2020) (2)
- Protein activation mapping and exploratory predictive markers for pCR in triple-negative breast cancer patients treated with neratinib in the I-SPY 2 TRIAL. (2015) (2)
- WORTH OF PERFECT INFORMATION (1991) (2)
- Basic Principles in Designing and Analyzing Clinical Studies (2016) (2)
- Meta-analyses of colorectal cancer risk factors Constance M. JohnsonCaimiao WeiJoe E. Ensor • Derek J. SmolenskiChristopher I. AmosBernard Levin • (2013) (2)
- Modulation of Chemotherapeutic Efficacy by Vascular Disrupting Agents: Optimizing the Sequence (2012) (1)
- Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma (2020) (1)
- Adaptive Clinical Trials (2011) (1)
- Major changes in breast cancer incidence in the United States over the period 2002 to 2004 (2007) (1)
- Abstract 2611: Evaluation of ANG/TIE/hypoxia pathway genes and signatures as predictors of response to trebananib (AMG 386) in the neoadjuvant I-SPY 2 TRIAL for Stage II-III high-risk breast cancer (2018) (1)
- Next generation clinical trials. (2011) (1)
- Commentary: the hazards of survival comparisons. (2007) (1)
- 90552 Evidence synthesis with reconstructed survival data (2021) (1)
- Concern Regarding Age Distribution of Breast Cancer. (2018) (1)
- A class of optimal stopping problems for sampling without replacement (1974) (1)
- Genome-Wide Profiling of Archived Material from CALGB 9840 and 9342 for Paclitaxel (P) and Trastuzumab (T) Response Biomarkers Using Gene Expression and Copy Number Analysis. (2009) (1)
- Abstract P2-14-01: The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL (2019) (1)
- NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and Survival (2011) (1)
- How does one teach anti-doping officials about evidence-based decision making ? Inferences about Testosterone Abuse among Athletes (2013) (1)
- Abstract 858: Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL (2016) (1)
- Abstract P3-07-49: Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial (2016) (1)
- [Inferences Using DNA Profiling in Forensic Identification and Paternity Cases]: Rejoinder (1991) (1)
- Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. (2010) (1)
- Predictive Biomarkers and Personalized Medicine p 53 Expression in Node-Positive Breast Cancer Patients : Results from the Cancer and Leukemia Group B 9344 Trial ( 159905 ) (2011) (1)
- Adaptive Randomization of Neratinib in Early Breast Cancer. (2016) (1)
- Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al. (2013) (1)
- Reply to M. Moroni and U. De Giorgi et al (2012) (1)
- S20 Changing the guidelines for breast cancer screening: modeling mammography benefits and harms (2011) (1)
- Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer (2017) (1)
- 18 Pursuing Molecular Stratification in Phase I Trials (2012) (1)
- Evidence synthesis with reconstructed survival data (2022) (1)
- Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma (2010) (1)
- Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840. (2009) (1)
- Abstract P2-20-02: Site of recurrence after neoadjuvant therapy: Clues to biology and impact on endpoints (2020) (1)
- Advances in drug development: Next generation clinical trials (2011) (1)
- One- and Two-Armed Bandit Problems (2006) (1)
- Incremental Benefit of Histamine Dihydrochloride When Added to Interleukin-2 for Remission Maintenance In Acute Myeloid Leukemia: A Bayesian Meta-Analysis (2010) (1)
- Neoadjuvant Response in the Context of a Biologically Defined Low or High Risk Tumor Has a Different Clinical Consequence, the I-SPY Trial (CALGB 150007/150012, ACRIN 6657). (2009) (1)
- Abstract PD1-03: Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) (2017) (1)
- Abstract P3-11-02: Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial (2020) (1)
- Accurate response assessment of breast cancer bone metastasis using computed tomography and new response criteria (2005) (1)
- Abstract PS4-08: Biomarker analysis of paclitaxel, ganitumab, and metformin (PGM) therapy in the I-SPY2 neoadjuvant clinical trial (2021) (0)
- Bayesian Statistics, Proceedings of the First International Meeting Held in Valencia (Spain), May 28 to June 2, 1979 (1983) (0)
- Decision Theory: Biostatistical Aspects (2014) (0)
- Investigational Drug Steering Committee Trial Design Task Force of the National Cancer Institute Therapeutics : Consensus Recommendations from the Clinical The Design of Phase II Clinical Trials Testing Cancer (2010) (0)
- Abstract 3417: The genomic landscape of canine melanoma reveals broad mutational heterogeneity and recurrent patterns of structural variation (2014) (0)
- Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI (2020) (0)
- I-SPY 2 low risk registry: An I-SPY 2 trial sub-study for women with clinically advanced, ER+, HER2- breast cancer and molecular good-prognosis gene signature. (2015) (0)
- Method of detection is a prognostic factor for outcome among women diagnosed with early stage breast cancer. (2009) (0)
- In reply [8] (2007) (0)
- In reply [14] (2005) (0)
- "-Omics" Approach to Adaptive Clinical Trials (2012) (0)
- Efficient dose-response finding strategies for acute neuroemergency treatments (2006) (0)
- Notation and preliminaries (1985) (0)
- In reply [12] (2005) (0)
- of HDC in the high-SDIP group is actually greater in the HmR- positive tumors. (2012) (0)
- Development of Breast Cancer Risk Prediction Model (2004) (0)
- The Effects of Single-Dose Atenolol, Labetalol, and Propranolol on Cardiac and Vascular Function (1987) (0)
- Response: Re: erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer (1999) (0)
- Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients ? Not Yet ! (2003) (0)
- Bioavailability: Designs and Analysis (2016) (0)
- Durvalumab With Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results From the Adaptively Randomized I-SPY2 Platform Trial (2020) (0)
- CTNI-02. TBCRC049: A PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF TUCATINIB, TRASTUZUMAB AND CAPECITABINE FOR THE TREATMENT OF LEPTOMENINGEAL METASTASIS IN HER2 POSITIVE BR1AST CANCER (2020) (0)
- Erratum: Identification of drug interactions by meta-analysis of premarketing trials: The effect of smoking on the pharmacokinetics and dosage requirements of flecainide acetate (Clinical pharmacology therapeutics (1989) 46 (1-8)) (1990) (0)
- Bayesian Statistics (2006) (0)
- Two independent Bernoulli arms; uniform discounting (1985) (0)
- Decision Analysis and Choosing Sample Size (2003) (0)
- DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial. (2017) (0)
- Distinguishing between CISNET model results versus CISNET models (2018) (0)
- Adaptive Designs of Clinical Trials (2003) (0)
- A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome (2004) (0)
- Bayesian analysis of lipid-lowering potentials of rosuvastatin and atorvastatin (2001) (0)
- Continuous-time bandits (1985) (0)
- Associate Editors Coordinating Editor and Applications Editor (1990) (0)
- Statistical Science Underlying Trial Design (2019) (0)
- Improved Outcomes From Adding Sequent ia l Pacl i taxe l but Not From Escalat ing Doxorubic in Dose in an Adjuvant Chemotherapy Regimen for Pat ients With Node-Pos i t i ve Pr imary Breast Cancer (2003) (0)
- Optimal Stopping Regions with Islands and Peninsulas (1982) (0)
- Abstract P3-08-04: Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer (2019) (0)
- for Certain Clinical Trials (2016) (0)
- Reply to V. Amoroso et al. (2015) (0)
- Clinical trial design (2003) (0)
- Book Reviews (2000) (0)
- Interpreting adjuvant breast cancer data in 2006 and beyond (2006) (0)
- Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply. (2018) (0)
- P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial. (2011) (0)
- The discount sequence (1985) (0)
- Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance. (2022) (0)
- Adapt ive Randomized Study of Idarubic in and Cytarabine Versus Troxaci tabine and Cytarabine Versus Troxaci tabine and Idarubic in in Untreated Pat ients 50 Years or Older With Adverse Karyotype Acute Myelo id Leukemia (2003) (0)
- Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer (2020) (0)
- A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance). (2018) (0)
- Accelerated Approval of Promising Agents in the Neoadjuvant Setting: A Path for Facilitating Targeted Drug Development for Breast Cancer (2013) (0)
- Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis (2015) (0)
- Herceptin Plus Chemotherapy Combination in Preoperative Regimen May Offer Clinical Benefit in Early Stage Breast Cancer (2005) (0)
- Book Review:Quantification and the Quest for Medical Certainty. J. Rosser Matthews (1997) (0)
- Many independent arms; geometric discounting (1985) (0)
- Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial (2020) (0)
- Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL (2015) (0)
- 3. Bayesian approaches to clinical trials and health‐care evaluation. David J. Spiegelhalter, Keith R. Abrams and Jonathan P. Myles, Wiley, Chichester, 2004. No. of Pages: 406. Price: £45.00, €67.50, $85.00. ISBN: 0‐471‐49975‐7 (2005) (0)
- Using Molecular Sizes of Simple Sequence Repeats vs. Discrete Binned Data in Assessing Probability of Ancestry (2005) (0)
- Overconfident Physician Opinion on the Effectiveness of BRCA1 Risk Reduction Measures (2001) (0)
- Abstract P2-11-01: Effects of radiotherapy on breast cancer outcomes among stage I, low-Recurrence risk, hormone-Sensitive breast cancer: Pooled analysis of individual data from phase III trials (2018) (0)
- Cancer Genomics : Promises and Complexities 1 (2001) (0)
- Title: the Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer Statement of Translational Relevance (2015) (0)
- Dose-Response T rial o f M egestrol A cetate i n A dvanced Breast C ancer: C ancer a nd L eukemia G roup B Phase I II S tudy 8 741 (1999) (0)
- Association of activation levels of TIE2 with response to the angiogenesis inhibitor trebananib in HER2+ patients in the I-SPY 2 trial. (2018) (0)
- A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome. (2004) (0)
- Author's response to reviews Title:Clinical Trialist perspectives on the Ethics of Adaptive Clinical Trials: A Mixed-Methods Analysis Authors: (2015) (0)
- Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL. (2018) (0)
- COMMENT ON: ERBB-2, P53, AND EFFICACY OF ADJUVANT THERAPY IN LYMPH NODE-POSITIVE BREAST CANCER. AUTHORS' REPLY (1999) (0)
- The best graph may be no graph (2008) (0)
- Computational analysis of drug-eluting stents, from deployment to drug delivery (2006) (0)
- Bibliography (1964) (0)
- Comment (2014) (0)
- Adjuvant Chemotherapy for Breast Cancer in Older Women (2009) (0)
- Prognostic a nd P redictive F actors f or P atients W ith Metastatic B reast C ancer U ndergoing A ggressive I nduction Therapy F ollowed b y H igh-Dose C hemotherapy W ith Autologous S tem-Cell S upport (2013) (0)
- Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies (2020) (0)
- The Past Is the Future (2005) (0)
- Abstract P3-06-15: Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 trial (2015) (0)
- Abstract P6-09-35: Proposal for a new breast cancer staging classification: Incorporating clinical and biologic factors (2017) (0)
- Abstract P6-10-06: Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy (2020) (0)
- SP005 Rationale of the design of the I-SPY trial (2013) (0)
- E13. If you want to publish, get your statistics right (2004) (0)
- [Bayes for Beginners? Some Reasons to Hesitate]: Reply (1997) (0)
- Independent Bernoulli arms (1985) (0)
- The superior laxative effects of psyllium over calcium polycarbophil in a dog model: Implications for human laxative users with high gastric pH (1998) (0)
- Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design (2019) (0)
- Probabilities of Winning a Certain Carnival Game (1978) (0)
- Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL (2015) (0)
- Developing and then Confirming a Hypothesis Based on a Chronology of Several Clinical Trials: A Bayesian Application to Pirfenidone Mortality Results (2020) (0)
- Bayesian model averaging in meta-analysis: Authors' response (2009) (0)
- Two arms, one arm known (1985) (0)
- Book reviews (1993) (0)
- Survival in previously treated advanced NSCLC: Pemetrexed versus best supportive care (BSC). (2006) (0)
- Abstract P5-11-18: Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial (2017) (0)
- Seymour Geisser, 1929–2004 (2005) (0)
- Abstract P3-06-37: I-SPY 2 qualifying biomarker evaluation (QBE): The challenge and opportunity for interrogating predicted pathways in an adaptive design biomarker rich trial (2015) (0)
- Correction: Principal Investigators for Mammography Schedule Models (2010) (0)
This paper list is powered by the following services:
Other Resources About Don Berry
What Schools Are Affiliated With Don Berry ?
Don Berry is affiliated with the following schools:
